Search

The Neuroscience of Parkinson's Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. The book also fills a much-needed gap as a'one-stop'synopsis of everything to do with the neurology and neuroscience related to Parkinson's disease—from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field. - Offers the most comprehensive coverage of a broad range of topics related to Parkinson's disease - Serves as a foundational collection for neuroscientists and neurologists on the biology of disease and brain dysfunction - Contains in each chapter an abstract, key facts, mini dictionary of terms, and summary points to aid in understanding - Features preclinical and clinical studies to help researchers map out key areas for research and further clinical recommendations - Serves as a'one-stop'source for everything you need to know about Parkinson's disease

Genetics, Neurology, Behavior, and Diet in Parkinson's Disease: The Neuroscience of Parkinson's Disease, Volume 2 provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. It fills a much-needed gap as a'one-stop'synopsis of everything to do with the neurology and neuroscience related to Parkinson's disease—from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field. - Offers the most comprehensive coverage of a broad range of topics related to Parkinson's disease - Serves as a foundational collection for neuroscientists and neurologists on the biology of disease and brain dysfunction - Contains in each chapter an abstract, key facts, mini dictionary of terms, and summary points to aid in understanding - Features preclinical and clinical studies to help researchers map out key areas for research and further clinical recommendations - Serves as a'one-stop'source for everything you need to know about Parkinson's disease

Motor dysfunction and cognitive impairment are major symptoms in both Huntington's Disease (HD) and Parkinson's Disease (PD). A breakthrough in HD research was the identification of the gene that causes this devastating monogenetic illness. Similarly, several genes were found to cause familial forms of PD. With their identification, a plethora of genetic animal models has been generated and has revolutionized the understanding of the pathobiology and pathophysiology of these disorders. The models allow us to study the earliest manifestations of the diseases behaviorally and neuropathologically and help us understand how they progress over time. Additionally, neurotoxic animal models are still of high interest to the PD field, as they are being used to study e.g. mitochondrial dysfunction in PD. This book focuses on animal models of both diseases and how they have helped and will continue to help understand the behavioral neurobiology in these disorders.

This book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from ‘bench to bedside'.Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; on going RCTs in LID and evidence-based medicine reviews of treatment options.Levodopa-Induced Dyskinesia in Parkinson's Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees and graduate and post-graduate students.

Recent research is leading to an ever-increasing range of investigative approaches whose aim is to achieve effective neuroprotective or neurorestorative treatment for individuals affected by Parkinson‘s disease. New directions under investigation reach beyond traditional pharmacological approaches to venture into innovative surgical methods, gene t

1h The 5 International Conference on the Progress in Alzheimer's Disease and Parkinson's 51 1 Disease took place from March 31 to April 5 \ 2001 in Kroto, Japan. This international 1 conference was organized as a joint Congress with the 9 International Catecholamine Symposium. A total of 1258 clinicians and researchers participated in this joint congress 1h from 38 countries in the world. This book represents the proceedings of the 5 Conference on Alzheimer's and Parkinson's disease. The International Conference on the Progress in Alzheimer's and Parkinson's disease was first launched by Professor Abraham Fisher of Israel and Professor Israel Hanin of USA. The first conference was held in Eilat, Israel in 1985. The second conference was organized in Kyoto, Japan in 1989; the third one in Chicago, USA, in 1993, and the fourth one in Eilat, Israel in 1997. The International Catecholamine Symposium (ICS) is an international meeting devoted to the development of basic as well as clinical research on catecholamines. The first Catecholamine Symposium was held in Bethesda, USA in 1958. Since then this symposium has occurred every 5 years. Professor Toshiharu Nagatsu was appointed as 1h the president of the 9 International Catecholamine Symposium, which was to be held in 200 I also in Japan. Therefore, we decided to organize a joint congress of the two meetings, because there is much overlap in research between Alzheimer's disease, Parkinson's disease, and catecholamines. We thank Professor Nagatsu very much for agreeing to organizing this joint congress.